Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

HealthLynked (HLYK) Long-Term Deferred Tax (2018 - 2022)

Historic Long-Term Deferred Tax for HealthLynked (HLYK) over the last 5 years, with Q4 2022 value amounting to $8.8 million.

  • HealthLynked's Long-Term Deferred Tax rose 7414.93% to $8.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was $8.8 million, marking a year-over-year increase of 7414.93%. This contributed to the annual value of $8.8 million for FY2022, which is 7414.93% up from last year.
  • According to the latest figures from Q4 2022, HealthLynked's Long-Term Deferred Tax is $8.8 million, which was up 7414.93% from $5.1 million recorded in Q4 2021.
  • HealthLynked's 5-year Long-Term Deferred Tax high stood at $8.8 million for Q4 2022, and its period low was $1.8 million during Q4 2018.
  • In the last 5 years, HealthLynked's Long-Term Deferred Tax had a median value of $4.7 million in 2020 and averaged $4.7 million.
  • In the last 5 years, HealthLynked's Long-Term Deferred Tax soared by 677.71% in 2021 and then skyrocketed by 7414.93% in 2022.
  • Quarter analysis of 5 years shows HealthLynked's Long-Term Deferred Tax stood at $1.8 million in 2018, then surged by 62.02% to $2.9 million in 2019, then surged by 63.03% to $4.7 million in 2020, then increased by 6.78% to $5.1 million in 2021, then surged by 74.15% to $8.8 million in 2022.
  • Its Long-Term Deferred Tax stands at $8.8 million for Q4 2022, versus $5.1 million for Q4 2021 and $4.7 million for Q4 2020.